The RSI Oscillator for ARRY moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 38 similar instances when the indicator left oversold territory. In 32 of the 38 cases the stock moved higher. This puts the odds of a move higher at 84%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ARRY just turned positive on October 27, 2026. Looking at past instances where ARRY's MACD turned positive, the stock continued to rise in 33 of 43 cases over the following month. The odds of a continued upward trend are 77%.
Following a +4.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARRY advanced for three days, in 194 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
ARRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARRY as a result. In 74 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ARRY entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.584) is normal, around the industry mean (2.576). P/E Ratio (-3.531) is within average values for comparable stocks, (5.140). Projected Growth (PEG Ratio) (0.399) is also within normal values, averaging (1.699). Dividend Yield (0.000) settles around the average of (0.057) among similar stocks. P/S Ratio (0.543) is also within normal values, averaging (5.133).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. ARRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
The RSI Oscillator for ETON moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 21 of the 22 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where ETON advanced for three days, in 243 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
ETON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ETON as a result. In 77 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
ETON moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ETON crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ETON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for ETON entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ETON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (30.783) is normal, around the industry mean (8.432). ETON has a moderately high P/E Ratio (109.065) as compared to the industry average of (-1.821). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (15.798) is also within normal values, averaging (178.797).
ARRY | ETON | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 8 | |
SMR RATING 1..100 | 100 | 28 | |
PRICE GROWTH RATING 1..100 | 88 | 35 | |
P/E GROWTH RATING 1..100 | 11 | 20 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARRY's Valuation (12) in the Biotechnology industry is significantly better than the same rating for ETON (89) in the Pharmaceuticals Major industry. This means that ARRY’s stock grew significantly faster than ETON’s over the last 12 months.
ETON's Profit vs Risk Rating (8) in the Pharmaceuticals Major industry is significantly better than the same rating for ARRY (100) in the Biotechnology industry. This means that ETON’s stock grew significantly faster than ARRY’s over the last 12 months.
ETON's SMR Rating (28) in the Pharmaceuticals Major industry is significantly better than the same rating for ARRY (100) in the Biotechnology industry. This means that ETON’s stock grew significantly faster than ARRY’s over the last 12 months.
ETON's Price Growth Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for ARRY (88) in the Biotechnology industry. This means that ETON’s stock grew somewhat faster than ARRY’s over the last 12 months.
ARRY's P/E Growth Rating (11) in the Biotechnology industry is in the same range as ETON (20) in the Pharmaceuticals Major industry. This means that ARRY’s stock grew similarly to ETON’s over the last 12 months.
| ARRY | ETON | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 84% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 84% | 1 day ago 80% |
| MACD ODDS (%) | 1 day ago 77% | N/A |
| TrendWeek ODDS (%) | 1 day ago 79% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 80% |
| Advances ODDS (%) | 7 days ago 77% | 1 day ago 84% |
| Declines ODDS (%) | 2 days ago 89% | 9 days ago 79% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 86% |
| Aroon ODDS (%) | 1 day ago 84% | 1 day ago 80% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARRY’s FA Score shows that 2 FA rating(s) are green while ETON’s FA Score has 3 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARRY’s TA Score shows that 5 TA indicator(s) are bullish while ETON’s TA Score has 4 bullish TA indicator(s).
ARRY (@Alternative Power Generation) experienced а +1.80% price change this week, while ETON (@Pharmaceuticals: Generic) price change was +1.93% for the same time period.
The average weekly price growth across all stocks in the @Alternative Power Generation industry was -1.46%. For the same industry, the average monthly price growth was -11.57%, and the average quarterly price growth was -39.26%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.92%. For the same industry, the average monthly price growth was -10.60%, and the average quarterly price growth was +6.14%.
ARRY is expected to report earnings on Nov 05, 2026.
ETON is expected to report earnings on Nov 05, 2026.
The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.
@Pharmaceuticals: Generic (-2.92% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.